Clinical Trial Update: Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for rovalpituzumab tesirine in DL3-expressing advanced solid tumors shows termination with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High Grade Gastroenteropancreatic Neuroendocrine Carcinoma
• Large Cell Neuroendocrine Carcinoma
• Malignant Melanoma
• Medullary Thyroid Cancer
• Neuroendocrine Prostate Cancer
• Other Neuroendocrine Carcinoma
• Other Solid Tumors

Drugs mentioned

• rovalpituzumab tesirine (rovalpituzumab tesirine)

Snippet

Sponsor: AbbVie | Conditions: Malignant Melanoma, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-10-19